Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,498 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | HealthPartners InstituteOTHER | 0 | May 7, 2020 | clinicaltrials |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma(HIPEC) | withdrawn | Phase 2 | 0 | Krankenhaus Barmherzige Schwestern LinzOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT03836157 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02948101 | PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT03147196 | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 22, 2019 | clinicaltrials |
| NCT03323710 | Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Military Institute od Medicine National Research InstituteOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT03419130 | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT03226236 | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC(RENALVax-2) | withdrawn | Phase 2 | 0 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT02962804 | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | University of Kansas Medical CenterOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00598858 | Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate(2007-5904) | withdrawn | Phase 2 | 0 | John P. FruehaufOTHER | 0 | Dec 8, 2016 | clinicaltrials |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT00556205 | Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 0 | Mar 24, 2016 | clinicaltrials |
| NCT02014831 | Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)(PENILANE) | withdrawn | Phase 2 | 0 | Centre Leon BerardOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01368003 | STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling | withdrawn | Phase 2 | 0 | Toni Choueiri, MDOTHER | 1 | Sep 1, 2015 | clinicaltrials |
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | withdrawn | Phase 2 | 0 | Hoosier Cancer Research NetworkOTHER | 0 | Aug 19, 2015 | clinicaltrials |
| NCT00574483 | Treatment of Advanced Renal Cell Carcinoma With Quinacrine | withdrawn | Phase 2 | 0 | Cleveland BioLabsINDUSTRY | 1 | Aug 3, 2015 | clinicaltrials |
| NCT01561482 | Study of Metformin With Simvastatin for Men With Prostate Carcinoma | withdrawn | Phase 2 | 0 | Nicholas MitsiadesOTHER | 1 | Jul 22, 2015 | clinicaltrials |
| NCT00176280 | Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | University of KentuckyOTHER | 0 | Jun 18, 2015 | clinicaltrials |
| NCT02235324 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT01943058 | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 0 | Sep 10, 2014 | clinicaltrials |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) | withdrawn | Phase 1 / Phase 2 | 0 | Emmanuel Antonarakis, MDOTHER | 1 | Jul 23, 2014 | clinicaltrials |
| NCT01907308 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 0 | Apr 29, 2014 | clinicaltrials |
| NCT01982487 | Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 18, 2013 | clinicaltrials |
| NCT00003517 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00040989 | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01616186 | Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | Andrea HarzstarkOTHER | 0 | Apr 8, 2013 | clinicaltrials |
| NCT01663415 | A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Sep 17, 2012 | clinicaltrials |
| NCT01070186 | Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 31, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jul 27, 2020source: clinicaltrials